Home Institutions Yale clinical trials Institution Directory
Clinical trials at Yale Sites in New Haven, CT
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:05 AM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1243
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 121–132 of 1,243 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions Small Cell Lung Cancer
Interventions ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin Drug
Lead sponsor AbbVie Industry
Eligibility 18 Years and older
Enrollment 180 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2031
U.S. locations 12
States / cities New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more
Conditions Multiple Myeloma
Interventions Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, Carfilzomib Drug
Lead sponsor Hoffmann-La Roche Industry
Eligibility 18 Years and older
Enrollment 380 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2033
U.S. locations 10
States / cities Duarte, California • Irvine, California • New Haven, Connecticut + 7 more
Conditions Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent) Biological · Drug
Lead sponsor Merck Sharp & Dohme LLC Industry
Eligibility 18 Years and older · Female only
Enrollment 770 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2032
U.S. locations 38
States / cities Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 34 more
Conditions Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Interventions silevertinib in combination with temozolomide, temozolomide (TMZ) Drug
Lead sponsor Black Diamond Therapeutics, Inc. Industry
Eligibility 18 Years and older
Enrollment 162 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 33
States / cities Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 28 more
Conditions HIV-1-infection
Interventions GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF Drug
Lead sponsor Gilead Sciences Industry
Eligibility 18 Years and older
Enrollment 700 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2033
U.S. locations 12
States / cities Torrance, California • New Haven, Connecticut • Ft. Pierce, Florida + 8 more
Conditions EGFR Inhibitor-associated Rash
Interventions ATR04-484, Vehicle Drug
Lead sponsor Azitra Inc. Industry
Eligibility 18 Years and older
Enrollment 32 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2027
U.S. locations 6
States / cities Hot Springs, Arkansas • New Haven, Connecticut • New York, New York + 3 more
Conditions Cancer of the Breast, Chemotherapy-induced Neuropathy
Interventions Tango Behavioral
Lead sponsor Ohio State University Comprehensive Cancer Center Other
Eligibility 40 Years and older
Enrollment 140 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2029
U.S. locations 2
States / cities New Haven, Connecticut • Columbus, Ohio
Conditions Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions Cytology Specimen Collection Procedure Other
Lead sponsor National Cancer Institute LAO Other
Eligibility 2 Months and older
Enrollment 5,000 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2015 – 2028
U.S. locations 139
States / cities Birmingham, Alabama • Fort Smith, Arkansas • Arroyo Grande, California + 94 more
Conditions Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib Procedure · Biological · Drug
Lead sponsor SWOG Cancer Research Network Network
Eligibility 18 Minutes and older
Enrollment 56 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2028
U.S. locations 278
States / cities Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more
Conditions Metastatic Colorectal Cancer
Interventions Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI, FoundationOne®Liquid CDx Drug · Diagnostic Test
Lead sponsor Hoffmann-La Roche Industry
Eligibility 18 Years and older
Enrollment 542 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2021 – 2030
U.S. locations 35
States / cities Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
Conditions Epilepsy, Epilepsy (Treatment Refractory)
Interventions Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system) Device
Lead sponsor Epiminder America, Inc. Industry
Eligibility 18 Years to 75 Years
Enrollment 210 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2027
U.S. locations 21
States / cities Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 17 more
Conditions Prostatic Cancer, Castration-Resistant
Interventions JSB462, AAA617 Drug
Lead sponsor Novartis Pharmaceuticals Industry
Eligibility 18 Years and older · Male only
Enrollment 138 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2028
U.S. locations 10
States / cities Duarte, California • Santa Monica, California • Denver, Colorado + 7 more About this Yale institution page
What this page lists ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , trials led by Yale University at any site , browse by condition , or browse by U.S. city .